XML 47 R30.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements - Estimated Fair Value of Significant Unobservable Inputs (Details)
Mar. 31, 2021
Humabs | Clinical and Regulatory Milestones | Discount Rates | Minimum  
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]  
Fair value contingent consideration measurement input 0.05 [1]
Humabs | Clinical and Regulatory Milestones | Discount Rates | Maximum  
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]  
Fair value contingent consideration measurement input 0.08 [1]
Humabs | Clinical and Regulatory Milestones | Discount Rates | Weighted Average  
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]  
Fair value contingent consideration measurement input 0.05 [1]
Humabs | Clinical and Regulatory Milestones | Probability of Achievement | Minimum  
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]  
Fair value contingent consideration measurement input 0.14 [1]
Humabs | Clinical and Regulatory Milestones | Probability of Achievement | Maximum  
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]  
Fair value contingent consideration measurement input 0.72 [1]
Humabs | Clinical and Regulatory Milestones | Probability of Achievement | Weighted Average  
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]  
Fair value contingent consideration measurement input 0.60 [1]
Humabs | Commercial Milestones | Discount Rates  
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]  
Fair value contingent consideration measurement input 0.11 [2]
Humabs | Commercial Milestones | Probability of Achievement | Minimum  
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]  
Fair value contingent consideration measurement input 0.14 [2]
Humabs | Commercial Milestones | Probability of Achievement | Maximum  
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]  
Fair value contingent consideration measurement input 0.72 [2]
Humabs | Commercial Milestones | Probability of Achievement | Weighted Average  
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]  
Fair value contingent consideration measurement input 0.67 [2]
Humabs | Commercial Milestones | Volatility  
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]  
Fair value contingent consideration measurement input 0.60 [2]
TomegaVax | Discount Rates | Minimum  
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]  
Fair value contingent consideration measurement input 0.00 [3]
TomegaVax | Discount Rates | Maximum  
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]  
Fair value contingent consideration measurement input 0.002 [3]
TomegaVax | Discount Rates | Weighted Average  
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]  
Fair value contingent consideration measurement input 0.002 [3]
TomegaVax | Measurement Input, Price Volatility  
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]  
Fair value contingent consideration measurement input 0.90 [3]
[1] Unobservable inputs were weighted based on the relative fair value of the clinical and regulatory milestone payments.
[2] Unobservable inputs were weighted based on the relative fair value of the commercial milestone payments
[3] Unobservable inputs were weighted based on the relative fair value of the underlying milestones